| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
After 95 years, it's time to eRASe JMML
|
Meynier, Sonia
|
|
|
43 |
C |
p.
|
artikel
|
| 2 |
BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting
|
Przespolewski, Amanda C.
|
|
|
43 |
C |
p.
|
artikel
|
| 3 |
Can we prevent or treat graft-versus-host disease with cellular-therapy?
|
Zahid, Mohammad Faizan
|
|
|
43 |
C |
p.
|
artikel
|
| 4 |
Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer
|
Costa-Silva, T.A.
|
|
|
43 |
C |
p.
|
artikel
|
| 5 |
Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation
|
Kanapuru, Bindu
|
|
|
43 |
C |
p.
|
artikel
|
| 6 |
Peripheral neuropathy in hematologic malignancies – Past, present and future
|
Li, Tiffany
|
|
|
43 |
C |
p.
|
artikel
|
| 7 |
The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia
|
Bewersdorf, Jan Philipp
|
|
|
43 |
C |
p.
|
artikel
|
| 8 |
Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications
|
Bernardo, Paula Sabbo
|
|
|
43 |
C |
p.
|
artikel
|
Tijdschrift beschrijving